Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) has already accomplished something most gene-editing companies are still trying to do: get a CRISPR-based medicine approved and onto the market. Now it has to prove it can build a business around the technology.

That starts with Casgevy, the gene-edited treatment for sickle cell disease developed with Vertex Pharmaceuticals (NASDAQ: VRTX). Casgevy generated $76 million in Q2 2026 revenue, up 78% sequentially and 151% year over year. It's now approved in 39 countries, and the FDA recently expanded its U.S. label to children as young as 2.

CRISPR Therapeutics receives 40% of Casgevy's profits and costs, while Vertex handles commercialization and manufacturing. That's a good foundation. But five years from now, I suspect Casgevy won't be the primary reason you'll want to own the stock.

Continue reading